AI Article Synopsis
- Resistance to ROS1 inhibitors, such as entrectinib, is common in non-small cell lung cancer (NSCLC).
- A specific case showed that a patient experienced tumor improvement when switched to crizotinib after developing resistance to entrectinib due to polysomy.
- This evidence indicates that crizotinib may still be a viable treatment option for NSCLC patients with polysomy, even after progression on entrectinib.
Article Abstract
Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of rearranged NSCLC that responded to crizotinib after tumor progression due to polysomy during entrectinib treatment. This case suggests that crizotinib is an effective option for patients with polysomy, even after disease progression on entrectinib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242555 | PMC |
| http://dx.doi.org/10.1016/j.jtocrr.2023.100523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report.
Front Oncol
December 2024
Department of Medical Oncology, International Ward, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
Background: ROS1, a member of the sevenless subfamily of tyrosine kinase insulin receptors, promotes tumor cell survival, proliferation, and metastasis by activating the JAK/STAT, PI3K/AKT, and MAPK/ERK pathways. It only accounts for about 2% of total NSCLC cases. No cases of acquired ROS-1 rearrangement have been reported worldwide.
View Article and Find Full Text PDFHistology Agnostic Drug Development: An Updated Review.
Cancers (Basel)
October 2024
Touro University Nevada College of Osteopathic Medicine, 874 American Pacific Dr, Henderson, NV 89014, USA.
Recent advancements in oncology have led to the development of histology-agnostic therapies, which target genetic alterations irrespective of the tumor's tissue of origin. This review aimed to provide a comprehensive update on the current state of histology-agnostic drug development, focusing on key therapies, including pembrolizumab, larotrectinib, entrectinib, dostarlimab, dabrafenib plus trametinib, selpercatinib, trastuzumab deruxtecan, and reprotrectinib. We performed a detailed analysis of each therapy's mechanism of action, clinical trial outcomes, and associated biomarkers.
View Article and Find Full Text PDFRedefining pancreatic cancer management with tumor-agnostic precision medicine.
Carcinogenesis
November 2024
Early-Phase Drug Development, Sarah Cannon Research Institute, 335 24th Avenue North Suite 300, Nashville, TN 37203, United States.
Precision oncology and tumor-agnostic drug development provide hope for enhancing outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged across various tumor types, driven by insights into shared biomarkers. In the case of pancreatic cancer, the prevalence of the KRAS gene mutation is noteworthy.
View Article and Find Full Text PDFGene-expression profile analysis to disclose diagnostics and therapeutics biomarkers for thyroid carcinoma.
Comput Biol Chem
December 2024
Bioinformatics Lab (Dry), Department of Statistics, University of Rajshahi, Rajshahi 6205, Bangladesh. Electronic address:
Article Synopsis
- Thyroid carcinoma (THCA) is the most common endocrine cancer in the head and neck, with ongoing research investigating its genetic links and molecular mechanisms, which are still not fully understood.
- While drug therapies are the main treatment for advanced THCA, many patients develop resistance over time, highlighting the need for multi-targeted drug therapies.
- A study identified 80 differentially expressed genes related to THCA and pinpointed eight key genes (some upregulated, some downregulated) that could serve as potential biomarkers for diagnosis and prognosis.
Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions.
Cancers (Basel)
October 2024
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
fusions are oncogenic drivers for multiple tumor types. Therefore, the development of selective tropomyosin receptor kinase (TRK) inhibitors, including larotrectinib and entrectinib, has been transformative in the context of clinical management, given the high rates of responses to these drugs, including intracranial responses in patients with brain metastases. Given their promising activity in pan-cancer cohorts, larotrectinib and entrectinib received U.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!